Compare CZWI & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | CRDL |
|---|---|---|
| Founded | 1938 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.8M | 226.6M |
| IPO Year | 2006 | 2017 |
| Metric | CZWI | CRDL |
|---|---|---|
| Price | $21.36 | $1.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $22.25 | $8.42 |
| AVG Volume (30 Days) | 32.0K | ★ 1.4M |
| Earning Date | 10-30-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ 8.96 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.70 | N/A |
| Revenue Next Year | $10.98 | N/A |
| P/E Ratio | $42.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.30 | $0.88 |
| 52 Week High | $24.43 | $2.34 |
| Indicator | CZWI | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 20.94 |
| Support Level | $20.42 | $0.96 |
| Resistance Level | $21.69 | $1.35 |
| Average True Range (ATR) | 0.45 | 0.08 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 40.76 | 2.40 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short - term investments; and funds provided from operations.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.